FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056291238> ?p ?o ?g. }

• W2056291238 endingPage "11" @default.
• W2056291238 startingPage "3" @default.
• W2056291238 abstract "No AccessJournal of UrologyClinical Urology: Review Article1 Jul 1999INTRAVESICAL CAPSAICIN AND RESINIFERATOXIN THERAPY: SPICING UP THE WAYS TO TREAT THE OVERACTIVE BLADDER MICHAEL B. CHANCELLOR and WILLIAM C. de GROAT MICHAEL B. CHANCELLORMICHAEL B. CHANCELLOR More articles by this author and WILLIAM C. de GROATWILLIAM C. de GROAT More articles by this author View All Author Informationhttps://doi.org/10.1097/00005392-199907000-00002AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Pharmacological treatment of the overactive bladder relies on partially blocking the efferent parasympathetic innervation to the detrusor with anticholinergic drugs. However, often these drugs have troublesome side effects and doses are insufficient to restore continence in patients with detrusor instability. We present the background, basic and clinical research with intravesical instillation of capsaicin and resiniferatoxin as treatments for the overactive bladder. Materials and Methods: Capsaicin, the main pungent ingredient in hot peppers of the genus Capsicum, is a specific neurotoxin that desensitizes C fiber afferent neurons which may be responsible for signals that trigger detrusor overactivity. Results: In the last 6 years studies have demonstrated encouraging improvement in lower urinary tract symptoms with minimal long-term complications. Most of these studies have also demonstrated that the acute pain and irritation associated with capsaicin are major deterrents to widespread use. Therefore, resiniferatoxin, an ultra-potent analogue of capsaicin which appears to have similar efficacy but less acute side effects, may be more useful. Conclusions: Intravesical capsaicin and resiniferatoxin are novel and promising treatments for the overactive bladder, with profound basic and clinical implications. References 1 : The influence of urinary incontinence on the quality of life of elderly women. Age Ageing1993; 22: 82. Google Scholar 2 : Incontinence in women: different response rates may introduce bias in community studies of pad consumption. J. Epid. Commun. Health1994; 48: 419. Google Scholar 3 : Urinary incontinence. Clin. Geriatr. Med1998; 14: 285. Google Scholar 4 : Urinary incontinence and neurological implication. In: . Boston: Butterworth Heinemann1995: 259. chapt. 28. Google Scholar 5 : Pharmacologic options for the overactive bladder. Urology1998; 51: 43. Google Scholar 6 : Pharmacologic treatment of lower urinary tract dysfunction in geriatric patients. Amer. J. Med. Sci1997; 314: 262. Google Scholar 7 : The “costs” of urinary incontinence. Eur. Urol1997; 2: 13. Google Scholar 8 : Urinary incontinence: steps to evaluation, diagnosis, and treatment. Nurse Pract1997; 22: 21. Google Scholar 9 : Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auto. Nerv. Syst1990; 30: S71. Google Scholar 10 : Should we be using chili pepper extracts to treat the overactive bladder?. J. Urol1997; 158: 2097. Link, Google Scholar 11 : The capsaicin-sensitive innervation of the rat urinary bladder: further studies on mechanisms regulating micturition threshold. J. Urol1986; 136: 696. Link, Google Scholar 12 : Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex of humans. J. Urol1989; 142: 150. Abstract, Google Scholar 13 : Intravesical capsaicin for neurogenic bladder dysfunction (Letter to the Editor). Lancet1992; 339: 1239. Google Scholar 14 : Effects of spinal cord injury on neurofilament immunoreactivity and capsaicin sensitivity in rat dorsal root ganglion neurons innervating the urinary bladder. Neuroscience1998; 83: 633. Google Scholar 15 : Excitatory effect of substance P in parasympathetic ganglia of cat urinary bladder. Amer. J. Physiol1989; 257: R1450. Google Scholar 16 : Role of the nerve terminals in the mechanism of inflammatory reactions. Bull. Millard Fillmore Hosp1960; 7: 53. Google Scholar 17 : The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Brit. J. Pharmacol1968; 33: 32. Google Scholar 18 : Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory-neurons. Pharmacol. Rev1991; 43: 143. Google Scholar 19 : Regional differences in the motor response to capsaicin in the guinea pig urinary bladder: relative role of pre- and postjunctional factors related to neuropeptide-containing sensory nerves. Neuroscience1988; 27: 675. Google Scholar 20 : Capsaicin and primary afferent neurons: from basic science to human therapy?. J. Auto. Nerv. Syst1991; 33: 1. Google Scholar 21 : Columbus, capsicum and capsaicin: past, present and future. Acta Physiol. Hung1987; 69: 265. Google Scholar 22 : Capsaicin type pungent agents producing pyrexia. In: . New York: Springer-Verlag1982: 437. Google Scholar 23 : Chilies: from antiquity to urology. Brit. J. Urol1997; 80: 845. Google Scholar 24 : The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature1997; 389: 816. Google Scholar 25 : Functional and fine structural characteristics of the sensory neuron blocking effect of capsaicin. Naunyn Schmiedebergs Arch. Pharmacol1975; 287: 157. Google Scholar 26 : Some like it hot: spicing up ion channels. Nature1997; 389: 783. Google Scholar 27 : Columbus, capsicum and capsaicin: past, present and future. Acta Physiol. Hungarica1987; 69: 265. Google Scholar 28 : Why red-hot peppers are red-hot. Biophoto. Int. J1998; 50: 40. Google Scholar 29 : Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain1996; 68: 195. Google Scholar 30 : Long-lasting desensitization of bladder afferents following intravesical resiniferatoxin and capsaicin in the rat. Pain1995; 61: 317. Google Scholar 31 : The neuropharmacology of capsaicin: review of some recent observations. Pharmacol. Rev1986; 38: 179. Google Scholar 32 : Calcitonin gene-related peptide (CGRP) in the female rat urogenital tract. Peptides1985; 6: 809. Google Scholar 33 : Therapeutic potential of capsaicin-like molecules: studies in animals and humans. Life Sci1992; 51: 1777. Google Scholar 34 : Sensory substance P-innervation of the urinary bladder: possible site of action of capsaicin in causing urine retention in rats. Neuroscience1983; 10: 861. Google Scholar 35 : Capsaicin-induced depletion of substance P from primary sensory neurons. Brain Res1978; 152: 183. Google Scholar 36 : Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. Neuroscience1997; 76: 299. Google Scholar 37 : Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J. Immunol1996; 157: 4412. Google Scholar 38 : Effects of immune responses in rats after neuromanipulation with capsaicin. J. Immunopharmacol1991; 13: 21. Google Scholar 39 : Electrophysiological study of micturition reflexes in rats. J. Physiol1989; 257: R410. Google Scholar 40 : Effect of capsaicin on micturition and associated reflexes in rats. Amer. J. Physiol1993; 34: R132. Google Scholar 41 : Effect of capsaicin on micturition and associated reflexes in chronic spinal rats. Brain Res1995; 678: 40. Google Scholar 42 : The effects of topical capsaicin on rat urinary bladder motility in vivo. Eur. J. Pharmacol1984; 103: 41. Google Scholar 43 : The effect capsaicin pretreatment on the cystometrograms of urethrane anesthetized rats. J. Urol1985; 133: 700. Abstract, Google Scholar 44 : Systemic capsaicin treatment impairs the micturition reflex in the rat. Brit. J. Pharmacol1984; 83: 935. Google Scholar 45 : Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab. Invest1997; 77: 37. Google Scholar 46 : Capsaicin-induced bladder overactivity and nociceptive behavior in conscious rats: involvement of spinal nitric oxide. J. Auto. Nerv. Sys1997; 67: 184. Google Scholar 47 : Capsaicin-induced nitric-oxide-dependent relaxation in isolated dog urethra. Eur. J. Pharmacol.1997; 335: 211. Google Scholar 48 : DMSO: effect on bladder afferent neurons and nitric oxide release. J. Urol.1997; 158: 1989. Link, Google Scholar 49 : Urodynamic effects of intravesical resiniferatoxin and capsaicin in conscious rats with and without outflow obstruction. J. Urol.1995; 154: 611. Link, Google Scholar 50 : Effect of intravesical capsaicin and vehicle on bladder integrity control and spinal cord injured rats. J. Urol.1998; 159: 1074. Google Scholar 51 : Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J. Urol.1996; 156: 947. Link, Google Scholar 52 : Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol. Neurosurg. Psych.1994; 57: 169. Google Scholar 53 : Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J. Urol.1995; 154: 1825. Link, Google Scholar 54 : Intravesical capsaicin in neurogenic impaired patients with detrusor hyperreflexia. J. Spinal Cord Med.1996; 19: 190. Google Scholar 55 : Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. J. Urol.1997; 158: 2087. Link, Google Scholar 56 : Intravesical capsaicin for treatment of autonomic dysreflexia in patients with spinal cord injury. J. Urol.1996; 155: 591A. abstract 1123. Google Scholar 57 : Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J. Urol.1997; 157: 585. Link, Google Scholar 58 : The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord1998; 36: 95. Google Scholar 59 : Intravesical capsaicin for interstitial cystitis. J. Urol.1997; 157: 254A. abstract 995. Google Scholar 60 : Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet1997; 350: 640. Google Scholar 61 : Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J. Urol.1997; 158: 2093. Link, Google Scholar 62 : Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin. J. Urol.1998; 159: 83. abstract 316. Google Scholar 63 : Treating the human bladder with capsaicin: is it safe?. Eur. Urol.1998; 33: 28. Google Scholar From the Department of Pharmacology, Division of Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PennsylvaniaFinancial interest and/or other relationship with Afferon Corporation.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byTai C, Ogagan P, Chen G, Larson J, Shen B, Wang J, Roppolo J and de Groat W (2018) Involvement of Opioid Receptors in Inhibition of Bladder Overactivity Induced by Foot Stimulation in CatsJournal of Urology, VOL. 188, NO. 3, (1012-1016), Online publication date: 1-Sep-2012.Frenkl T, Zhu H, Reiss T, Seltzer O, Rosenberg E and Green S (2018) A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive BladderJournal of Urology, VOL. 184, NO. 2, (616-622), Online publication date: 1-Aug-2010.Chuang Y, Lee W, Lee W and Chiang P (2018) Intravesical Liposome Versus Oral Pentosan Polysulfate for Interstitial Cystitis/Painful Bladder SyndromeJournal of Urology, VOL. 182, NO. 4, (1393-1400), Online publication date: 1-Oct-2009.Lazzeri M, Calò G, Spinelli M, Malaguti S, Guerrini R, Salvadori S, Beneforti P, Regoli D and Turini D (2018) Daily Intravesical Instillation of 1 mg Nociceptin/Orphanin FQ for the Control of Neurogenic Detrusor Overactivity: A Multicenter, Placebo Controlled, Randomized Exploratory StudyJournal of Urology, VOL. 176, NO. 5, (2098-2102), Online publication date: 1-Nov-2006.Green S, Alon A, Ianus J, McNaughton K, Tozzi C and Reiss T (2018) Efficacy and Safety of a Neurokinin-1 Receptor Antagonist in Postmenopausal Women With Overactive Bladder With Urge Urinary IncontinenceJournal of Urology, VOL. 176, NO. 6, (2535-2540), Online publication date: 1-Dec-2006.HANSEN J, MEDIA S, NØHR M, BIERING-SØRENSEN F, SINKJÆR T and RIJKHOFF N (2018) TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY IN SPINAL CORD INJURED PATIENTS BY CONDITIONAL ELECTRICAL STIMULATIONJournal of Urology, VOL. 173, NO. 6, (2035-2039), Online publication date: 1-Jun-2005.SEKI S, SASAKI K, IGAWA Y, NISHIZAWA O, CHANCELLOR M, de GROAT W and YOSHIMURA N (2018) Suppression of Detrusor-Sphincter Dyssynergia by Immunoneutralization of Nerve Growth Factor in Lumbosacral Spinal Cord in Spinal Cord Injured RatsJournal of Urology, VOL. 171, NO. 1, (478-482), Online publication date: 1-Jan-2004.de SÈZE M, WIART L, de SÈZE M, SOYEUR L, DOSQUE J, BLAJEZEWSKI S, MOORE N, BROCHET B, MAZAUX J, BARAT M and JOSEPH P (2018) Intravesical Capsaicin Versus Resiniferatoxin for the Treatment of Detrusor Hyperreflexia in Spinal Cord Injured Patients:: A Double-Blind, Randomized, Controlled StudyJournal of Urology, VOL. 171, NO. 1, (251-255), Online publication date: 1-Jan-2004.TYAGI P, CHANCELLOR M, LI Z, de GROAT W, YOSHIMURA N, FRASER M and HUANG L (2018) Urodynamic and Immunohistochemical Evaluation of Intravesical Capsaicin Delivery Using Thermosensitive Hydrogel and LiposomesJournal of Urology, VOL. 171, NO. 1, (483-489), Online publication date: 1-Jan-2004.SMITH C and CHANCELLOR M (2018) EMERGING ROLE OF BOTULINUM TOXIN IN THE MANAGEMENT OF VOIDING DYSFUNCTIONJournal of Urology, VOL. 171, NO. 6 Part 1, (2128-2137), Online publication date: 1-Jun-2004.GIANNANTONI A, DI STASI S, STEPHEN R, BINI V, COSTANTINI E and PORENA M (2018) INTRAVESICAL RESINIFERATOXIN VERSUS BOTULINUM-A TOXIN INJECTIONS FOR NEUROGENIC DETRUSOR OVERACTIVITY: A PROSPECTIVE RANDOMIZED STUDYJournal of Urology, VOL. 172, NO. 1, (240-243), Online publication date: 1-Jul-2004.YOKOYAMA T, NOZAKI K, FUJITA O, NOSE H, INOUE M and KUMON H (2018) ROLE OF C AFFERENT FIBERS AND MONITORING OF INTRAVESICAL RESINIFERATOXIN THERAPY FOR PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITYJournal of Urology, VOL. 172, NO. 2, (596-600), Online publication date: 1-Aug-2004. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 170, NO. 3, (826-827), Online publication date: 1-Sep-2003.COMITER C (2018) Sacral Neuromodulation for the Symptomatic Treatment of Refractory Interstitial Cystitis: A Prospective StudyJournal of Urology, VOL. 169, NO. 4, (1369-1373), Online publication date: 1-Apr-2003.YOSHIMURA N and CHANCELLOR M (2018) Current and Future Pharmacological Treatment for Overactive BladderJournal of Urology, VOL. 168, NO. 5, (1897-1913), Online publication date: 1-Nov-2002.Giannantoni A, Di Stasi S, Stephen R, Navarra P, Scivoletto G, Mearini E and Porena M (2018) Intravesical Capsaicin Versus Resiniferatoxin In Patients With Detrusor Hyperreflexia: A Prospective Randomized StudyJournal of Urology, VOL. 167, NO. 4, (1710-1714), Online publication date: 1-Apr-2002.SEKI N, IKAWA S, TAKANO N and NAITO S (2018) INTRAVESICAL INSTILLATION OF RESINIFERATOXIN FOR NEUROGENIC BLADDER DYSFUNCTION IN A PATIENT WITH MYELODYSPLASIAJournal of Urology, VOL. 166, NO. 6, (2368-2369), Online publication date: 1-Dec-2001.CHARTIER-KASTLER E, RUUD BOSCH J, PERRIGOT M, CHANCELLOR M, RICHARD F and DENYS P (2018) LONG-TERM RESULTS OF SACRAL NERVE STIMULATION (S3) FOR THE TREATMENT OF NEUROGENIC REFRACTORY URGE INCONTINENCE RELATED TO DETRUSOR HYPERREFLEXIAJournal of Urology, VOL. 164, NO. 5, (1476-1480), Online publication date: 1-Nov-2000.SCHURCH B, STÖHRER M, KRAMER G, SCHMID D, GAUL G and HAURI D (2018) BOTULINUM-A TOXIN FOR TREATING DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: A NEW ALTERNATIVE TO ANTICHOLINERGIC DRUGS? PRELIMINARY RESULTSJournal of Urology, VOL. 164, NO. 3 Part 1, (692-697), Online publication date: 1-Sep-2000.YOKOYAMA O, KOMATSU K, KODAMA K, YOTSUYANAGI S, NIIKURA S and NAMIKI M (2018) DIAGNOSTIC VALUE OF INTRAVESICAL LIDOCAINE FOR OVERACTIVE BLADDERJournal of Urology, VOL. 164, NO. 2, (340-343), Online publication date: 1-Aug-2000. Volume 162Issue 1July 1999Page: 3-11 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information MICHAEL B. CHANCELLOR More articles by this author WILLIAM C. de GROAT More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2056291238 created "2016-06-24" @default.
• W2056291238 creator A5076037136 @default.
• W2056291238 creator A5078179672 @default.
• W2056291238 date "1999-07-01" @default.
• W2056291238 modified "2023-10-15" @default.
• W2056291238 title "INTRAVESICAL CAPSAICIN AND RESINIFERATOXIN THERAPY: SPICING UP THE WAYS TO TREAT THE OVERACTIVE BLADDER" @default.
• W2056291238 cites W1511198581 @default.
• W2056291238 cites W1623772266 @default.
• W2056291238 cites W17244615 @default.
• W2056291238 cites W1970894908 @default.
• W2056291238 cites W1978832478 @default.
• W2056291238 cites W1979341296 @default.
• W2056291238 cites W1990799489 @default.
• W2056291238 cites W1991256305 @default.
• W2056291238 cites W1994235660 @default.
• W2056291238 cites W2002406661 @default.
• W2056291238 cites W2009336765 @default.
• W2056291238 cites W2017215494 @default.
• W2056291238 cites W2020708033 @default.
• W2056291238 cites W2024058549 @default.
• W2056291238 cites W2036625621 @default.
• W2056291238 cites W2038848442 @default.
• W2056291238 cites W2042443334 @default.
• W2056291238 cites W2046590018 @default.
• W2056291238 cites W2048426485 @default.
• W2056291238 cites W2052310808 @default.
• W2056291238 cites W2052460472 @default.
• W2056291238 cites W2057766082 @default.
• W2056291238 cites W2062233070 @default.
• W2056291238 cites W2064934743 @default.
• W2056291238 cites W2067556702 @default.
• W2056291238 cites W2070509782 @default.
• W2056291238 cites W2072091854 @default.
• W2056291238 cites W2073866586 @default.
• W2056291238 cites W2075292990 @default.
• W2056291238 cites W2076463081 @default.
• W2056291238 cites W2078601886 @default.
• W2056291238 cites W2088080391 @default.
• W2056291238 cites W2093202550 @default.
• W2056291238 cites W2103402799 @default.
• W2056291238 cites W2114530814 @default.
• W2056291238 cites W2124258764 @default.
• W2056291238 cites W2126178474 @default.
• W2056291238 cites W2143444946 @default.
• W2056291238 cites W2168334541 @default.
• W2056291238 cites W2322182246 @default.
• W2056291238 cites W2396561818 @default.
• W2056291238 cites W2415768030 @default.
• W2056291238 cites W2417084671 @default.
• W2056291238 cites W4238841974 @default.
• W2056291238 cites W4254660282 @default.
• W2056291238 doi "https://doi.org/10.1097/00005392-199907000-00002" @default.
• W2056291238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10379728" @default.
• W2056291238 hasPublicationYear "1999" @default.
• W2056291238 type Work @default.
• W2056291238 sameAs 2056291238 @default.
• W2056291238 citedByCount "261" @default.
• W2056291238 countsByYear W20562912382012 @default.
• W2056291238 countsByYear W20562912382013 @default.
• W2056291238 countsByYear W20562912382014 @default.
• W2056291238 countsByYear W20562912382015 @default.
• W2056291238 countsByYear W20562912382016 @default.
• W2056291238 countsByYear W20562912382017 @default.
• W2056291238 countsByYear W20562912382018 @default.
• W2056291238 countsByYear W20562912382020 @default.
• W2056291238 countsByYear W20562912382021 @default.
• W2056291238 countsByYear W20562912382022 @default.
• W2056291238 countsByYear W20562912382023 @default.
• W2056291238 crossrefType "journal-article" @default.
• W2056291238 hasAuthorship W2056291238A5076037136 @default.
• W2056291238 hasAuthorship W2056291238A5078179672 @default.
• W2056291238 hasConcept C126322002 @default.
• W2056291238 hasConcept C126894567 @default.
• W2056291238 hasConcept C142724271 @default.
• W2056291238 hasConcept C155164980 @default.
• W2056291238 hasConcept C160145004 @default.
• W2056291238 hasConcept C170493617 @default.
• W2056291238 hasConcept C204787440 @default.
• W2056291238 hasConcept C2776354303 @default.
• W2056291238 hasConcept C2777844464 @default.
• W2056291238 hasConcept C2778941218 @default.
• W2056291238 hasConcept C2779762690 @default.
• W2056291238 hasConcept C2780051329 @default.
• W2056291238 hasConcept C71924100 @default.
• W2056291238 hasConceptScore W2056291238C126322002 @default.
• W2056291238 hasConceptScore W2056291238C126894567 @default.
• W2056291238 hasConceptScore W2056291238C142724271 @default.
• W2056291238 hasConceptScore W2056291238C155164980 @default.
• W2056291238 hasConceptScore W2056291238C160145004 @default.
• W2056291238 hasConceptScore W2056291238C170493617 @default.
• W2056291238 hasConceptScore W2056291238C204787440 @default.
• W2056291238 hasConceptScore W2056291238C2776354303 @default.
• W2056291238 hasConceptScore W2056291238C2777844464 @default.
• W2056291238 hasConceptScore W2056291238C2778941218 @default.
• W2056291238 hasConceptScore W2056291238C2779762690 @default.
• W2056291238 hasConceptScore W2056291238C2780051329 @default.
• W2056291238 hasConceptScore W2056291238C71924100 @default.

• next